# Diabetes Research Hub — Monitor Report

**Run date:** 2026-07-23 (automated review run)
**Prepared by:** Hub Monitor (scheduled task)
**Scope:** Read-only review of `Analysis/Results/` outputs + web scan. No existing files modified.

---

## TL;DR — The thing you don't want to hear

**Your data pipelines are still stale, same as they were on 07-22.** The clinical-trials and PubMed snapshots have not advanced since **2026-07-17** — that is now **6 days old**. The gap analysis is fresh (07-22), but trial/PubMed intelligence is running on a week-old snapshot while three genuinely significant events landed in the last week (orforglipron→FDA for diabetes, retatrutide Phase 3 T2D data, Tzield pediatric approval). The monitor cannot detect changes that the underlying scripts never fetched. **Re-run `baseline_clinical_trials.py` and `baseline_pubmed_alerts.py` before trusting any "no change" signal below.** [Certain — file mtimes confirm it]

---

## File System Status

| File | Last modified | Age | Status |
|------|---------------|-----|--------|
| `clinical_trials_latest.json` | 2026-07-17 | 6 days | ⚠️ Stale |
| `pubmed_recent_latest.json` | 2026-07-17 | 6 days | ⚠️ Stale |
| `hub_monitor_report.md` | 2026-07-17 | 6 days | ⚠️ Stale (no scan 07-18→07-23) |
| `literature_gap_report.md` | 2026-07-22 | 1 day | ✅ Fresh |
| `literature_gap_data.json` | 2026-07-18 | 5 days | ◐ Aging |
| `Diabetes_Research_Tracker.xlsx` | 2026-07-17 | 6 days | ◐ Aging |
| Latest trial snapshot | `..._2026-07-17.json` | 6 days | ⚠️ No snapshot 07-18→07-23 |
| Latest PubMed snapshot | `..._2026-07-17.json` | 6 days | ⚠️ No snapshot 07-18→07-23 |

`agent_state.json` is updating daily (last 07-22), so the agent loop is alive — but the **data-refresh scripts specifically have not run since 07-17**. The hub's own review flag already noted "827 result files older than 14 days." This is a pipeline-scheduling gap, not a one-off.

---

## Clinical Trial Changes

Snapshot data unchanged since last real fetch (07-17). All figures below are from the **07-17 snapshot** and were already largely surfaced in the 07-17→07-22 reports. Nothing new can appear until the fetch script re-runs.

**Diff 07-15 → 07-17 (last real movement captured):**

- New: 2 (both COMPLETED admin entries — NCT05086445 Lilly orforglipron PK; NCT05574699 JHU social-risk CDS)
- Removed: 1 · Status changes: 3 · New results: 0
- The 3 status changes were the **AstraZeneca elecoglipron Phase 3 cluster** (NCT07662135 / 662044 / 662109) flipping `NOT_YET_RECRUITING → RECRUITING`. Already flagged 07-22.

**Key Phase 3 trials — current status (from 07-17 snapshot):** 52 Phase 3 trials in RECRUITING status. Highest-priority sponsors:

| NCT | Sponsor | Asset | Status |
|-----|---------|-------|--------|
| NCT06832410 / NCT04786262 | Vertex | VX-880 (zimislecel) | RECRUITING (P3) |
| NCT07222332 / NCT07222137 | Eli Lilly | Baricitinib (beta-cell preservation / Stage-3 delay) | RECRUITING (P3) |
| NCT07076199 | Novo Nordisk | Insulin icodec | RECRUITING (P3) |
| NCT07564414 | Novo Nordisk | CagriSema | RECRUITING (P3) |
| NCT07088068 | Sanofi | Teplizumab | RECRUITING (P3) |
| NCT06739122 | Eli Lilly | Dulaglutide (pediatric) | RECRUITING (P3) |

**Recently posted results worth reviewing** (from snapshot, newest first): NCT05086445 (Lilly orforglipron PK, 07-16); NCT05254002 (Bayer combination, P2, 07-13); NCT03263494 (Jaeb CGM in teens/young adults T1D, P3, 07-09); NCT04255433 (Lilly tirzepatide vs dulaglutide, P3, 07-08).

---

## PubMed Highlights

From `pubmed_recent_latest.json` (30-day lookback, generated 07-17; 158 unique papers, 16 domains). No newer PubMed pull exists.

**Cross-domain papers (highest priority — 12 total).** The two that sit on **Tier 1 intersections**:

- **[42459945]** *A framework for assessing algorithmic discrimination risks in training data: pediatric T1D* — **Diabetes AI/ML × Closed Loop AP × Diabetes Health Equity**. Triple-domain, spans two Tier 1 areas (AI/ML Prediction, Epi/Health Equity). Still the strongest synthesis candidate; carried over unactioned from 07-22.
- **[42458730]** & **[42459212]** — **Microbiome × Multi-Omics** pair (BMI response to diet; precision nutrition in Asian populations). Both touch Tier 1 Multi-Omics Biomarker Integration.

**Key-therapy mentions (30-day therapy_hits):** orforglipron (10 hits / 5 papers), CagriSema (6/5), retatrutide (4/4), teplizumab (4/4), icodec (3/3), dapagliflozin (52/5), baricitinib (2/2). **zimislecel = 0/0** — this is the known **alias defect**: zimislecel is the generic name for Vertex VX-880, which has two active Phase 3 trials. The tracker is blind to it because the alias map lacks `zimislecel ↔ VX-880`. [Certain — defect, flagged 07-22, still unfixed]

**Volume:** Flat and low (2 papers/domain cap in the snapshot's per-domain query design) — this is a query-design ceiling, not a real activity signal. Don't read domain-level trends from this file.

---

## Gap Analysis Summary

From `literature_gap_report.md` (generated 2026-07-22, fresh). 30 domains, 435 pairs. **Validation level: BRONZE** — single analytical source, expert confirmation required before any claim rises to SILVER.

**Top under-researched intersections (highest gap scores):**

1. Treg / CAR-T × Neuropathy — 100.0 (0 joint pubs)
2. Beta Cell Regen × Health Equity — 100.0 (0)
3. Treg / CAR-T × Health Equity — 100.0 (0)
4. Glucokinase × Health Equity — 100.0 (0)
5. Gene Therapy × LADA — 100.0 (0)

*(Also ranked 100.0: Drug Repurposing × Health Equity; then Insulin Resistance × Islet Transplant at 91.9.)*

**Alignment with our Tier 1 contribution areas:** Four of the top gaps route straight through Tier 1 territory — **Beta Cell Regen × Health Equity**, **Drug Repurposing × Health Equity**, and **Glucokinase × Health Equity** all intersect Tier 1 #4 (Drug Repurposing) and #6 (Epi/Health Equity); the **Microbiome × Multi-Omics** cross-domain papers above intersect Tier 1 #1 (Multi-Omics). These are the defensible places to spend compute. **Caveat:** a gap score of 100 with 0 joint pubs is exactly where terminology-artifact risk is highest — verify with a combined-term PubMed + Cochrane/PROSPERO check before treating any as a real hole.

---

## Breaking News (web scan, last 7 days)

Three items clear the "genuinely significant" bar; all involve therapies you already track, and **none are yet reflected in the 07-17 snapshot** — that is the cost of the stale pipeline.

- **Orforglipron → FDA for diabetes.** Lilly's oral GLP-1 (brand **Foundayo**, already approved for weight management) beat **oral semaglutide** on HbA1c across the Phase 3 **ACHIEVE** program and has been submitted to FDA for a type-2 diabetes indication. Greater weight loss but more GI AEs / discontinuations. [Likely — multiple secondary sources; confirm primary ACHIEVE readout]
- **Retatrutide first Phase 3 T2D + obesity data (ADA 2026).** Triple agonist (GIP/GLP-1/glucagon): HbA1c −1.7 to −1.9% vs −0.8% placebo; weight −11.5 to −15.3% vs −2.6% at 40 wks; benefit signals in OSA and knee OA pain. [Likely — ADA press + secondary; verify against NEJM/primary before recording above BRONZE]
- **Tzield (teplizumab) pediatric approval.** Supported by Phase 3 **PROTECT** (328 children/adolescents 8–17, recent-onset stage-3 T1D). Directly relevant to the Sanofi teplizumab P3 (NCT07088068) and Lilly baricitinib P3s in the tracker. [Likely]

**Still pending — confirm next run:** Lilly **insulin efsitora alfa** FDA decision was expected this month (T2D). Not yet resolved in sources scanned. [Guessing on timing — needs a targeted check]

---

## Recommended Actions

1. **Refresh the stale pipelines — this is blocking everything else.** Run `python baseline_clinical_trials.py` and `python baseline_pubmed_alerts.py`, then `python hub_monitor.py`. No trial/PubMed snapshot exists for 07-18 → 07-23. Until this runs, "0 changes" is not a finding — it is a blind spot.
2. **Investigate why the refresh scripts stopped on 07-17** while `agent_state.json` keeps updating. Six days of no data fetch with a live agent loop points to a broken/disabled schedule for the two baseline scripts specifically. Check their scheduler/cron entry.
3. **Fix the therapy-alias defect.** Add `zimislecel ↔ VX-880` to the alias map so the tracker stops reporting 0 activity for an active Phase 3 asset. [Certain defect — 3rd report flagging it]
4. **Update the tracker** (`Diabetes_Research_Tracker.xlsx`) with the newly-recruiting **AstraZeneca elecoglipron** Phase 3 cluster (NCT07662135/044/109) and the **Vertex VX-880 / zimislecel** P3 pair.
5. **Capture the three breaking-news events** in the trial-intelligence + evidence network once primary sources are available: orforglipron ACHIEVE (FDA filing), retatrutide P3 T2D, Tzield PROTECT. Cross-check every efficacy figure against the primary publication before recording above BRONZE.
6. **Action the carried-over synthesis candidate [42459945]** (AI/ML × Closed Loop × Health Equity) — two Tier 1 areas + a top-gap theme, now unactioned for a week. Either write it up or explicitly deprioritize it so it stops recurring.
7. **Promote one Tier 1-aligned gap to SILVER.** Best candidate: **Beta Cell Regen × Health Equity** or **Drug Repurposing × Health Equity**. Run combined-term PubMed + Cochrane/PROSPERO to confirm the gap is real before any write-up.
8. **Confirm the efsitora alfa FDA outcome** — decision was due this month; not resolved in this scan.

---

## Evidence / Provenance

- All trial and PubMed figures: read directly from `clinical_trials_latest.json` (07-17) and `pubmed_recent_latest.json` (07-17); snapshot diffs computed against `clinical_trials_snapshot_2026-07-15.json` and `..._2026-03-15.json`.
- Gap figures: read from `literature_gap_report.md` (07-22).
- Tier 1 definitions: `RESEARCH_DOCTRINE.md` §"TIER 1".
- Breaking news: web scan 2026-07-23; all items marked [Likely]/[Guessing] pending primary-source confirmation per Research Doctrine evidence levels.
- This run modified no existing files.

*Generated by the Diabetes Research Hub scheduled monitor — 2026-07-23.*
